Details of the Drug

General Information of Drug (ID: DMNKG1Z)

Drug Name

Atenolol

Synonyms

Aircrit; Alinor; Altol; Anselol; Antipressan; Atcardil; Atecard; Atehexal; Atenblock; Atendol; Atenet; Ateni; Atenil; Atenol; Atenolin; Atenololum; Atenomel; Atereal; Aterol; Betablok; Betacard; Betasyn; Blocotenol; Blokium; Cardaxen; Cardiopress; Corotenol; Cuxanorm; Duraatenolol; Duratenol; Evitocor; Farnormin; Hipres; Hypoten; Ibinolo; Internolol; Jenatenol; Juvental; Loten; Lotenal; Myocord; Neatenol; Normalol; Normiten; Noten; Oraday; Ormidol; Panapres; Plenacor; Premorine; Prenolol; Prenormine; Prinorm; Selobloc; Serten; Servitenol; Stermin; Tenidon; Tenobloc; Tenoblock; Tenolol; Tenoprin; Tenormin; Tenormine; Tensimin; Tensotin; Tredol; Unibloc; Uniloc; Vascoten; Vericordin; Wesipin; Xaten; Atenol AL; Atenol Atid; Atenol Cophar; Atenol Fecofar; Atenol GNR; Atenol Gador; Atenol Genericon; Atenol Heumann; Atenol MSD; Atenol NM Pharma; Atenol Nordic; Atenol PB; Atenol Quesada; Atenol Stada; Atenol Tika; Atenol Trom; Atenol acis; Atenol ct; Atenol von ct; Betatop Ge; Scheinpharm Atenol; Seles beta; Tenormine [French]; A 7655; Atenol 1A pharma; Apo-Atenolol; Atenol-Mepha; Atenol-Wolff; Atenol-ratiopharm; Atenololum [INN-Latin]; Felo-Bits; Lo-ten; Teno-basan; Tenormin (TN); Atenolol (JP15/USP/INN); Atenolol [USAN:INN:BAN:JAN]; Acetamide,2-(p-(2-hydroxy-3-(isopropylamino)propoxy)phenyl); (+-)-4-(2-Hydroxy-3-isopropylaminopropoxy)phenylacetamide; (+-)-Atenolol; (+/-)-4-[2-Hydroxy-3-[(1-methylethyl)amino]propoxy]benzeneacetamide; (1)-2-(4-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; (inverted question mark)-Atenolol; 1-p-Carbamoylmethylphenoxy-3-isopropylamino-2-propanol; 2-(4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl)acetamid; 2-(4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}phenyl)acetamide; 2-(p-(2-Hydroxy-3-(isopropylamino)propoxy)phenyl)acetamide; 2-[4-(2-Hydroxy-3-isopropylaminopropoxy)phenyl]acetamide; 2-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; 2-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; 4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)benzeneacetamide; 4-[2'-Hydroxy-3'-(isopropylamino)propoxy]phenylacetamide; 4-[2-Hydroxy-3-(isopropylamino)-propoxy]phenylacetamide

Indication

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[1], [2]

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

266.34

Topological Polar Surface Area (xlogp)

0.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability: 56% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The renal clearance of drug is 95-168 mL/min [5]
Elimination: 94% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 6 - 7 hours [6]
Metabolism: The drug is metabolized via the liver [7]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 12.50267 micromolar/kg/day [8]
Unbound Fraction: The unbound fraction of drug in plasma is 0.94% [6]
Vd: The volume of distribution (Vd) of drug is 63.8-112.5 L [5]
Water Solubility: The ability of drug to dissolve in water is measured as 24.8 mg/mL [3]

Chemical Identifiers

Formula: C14H22N2O3
IUPAC Name: 2-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide
Canonical SMILES: CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O
InChI: InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)
InChIKey: METKIMKYRPQLGS-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2249
ChEBI ID: CHEBI:2904
CAS Number: 29122-68-7
DrugBank ID: DB00335
TTD ID: D01UXC
VARIDT ID: DR00033
INTEDE ID: DR0617
ACDINA ID: D00048

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[9], [10]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic cation transporter 1 (SLC22A1)	DTT79CX	S22A1_HUMAN	Substrate	[11]
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[12]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[13]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[14]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[15]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Atenolol

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levamlodipine	DM92S6N	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Levamlodipine.	Hypertension [BA00-BA04]	[66]
Verapamil	DMA7PEW	Major	Increased risk of cardiac depression by the combination of Atenolol and Verapamil.	Hypertension [BA00-BA04]	[66]
Diltiazem	DMAI7ZV	Major	Increased risk of cardiac depression by the combination of Atenolol and Diltiazem.	Hypertension [BA00-BA04]	[66]
Amlodipine	DMBDAZV	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Amlodipine.	Hypertension [BA00-BA04]	[66]
Indapamide	DMGN1PW	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Indapamide.	Hypertension [BA00-BA04]	[67]
Trichlormethiazide	DMHAQCO	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Trichlormethiazide.	Hypertension [BA00-BA04]	[67]
Felodipine	DMOSW35	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Felodipine.	Hypertension [BA00-BA04]	[66]
Hydrochlorothiazide	DMUSZHD	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Hydrochlorothiazide.	Hypertension [BA00-BA04]	[67]
Clevidipine butyrate	DMW4M97	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Clevidipine butyrate.	Hypertension [BA00-BA04]	[66]
-----------


⏷ Show the Full List of 9 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Atenolol (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sucralfate	DMP9HBO	Minor	Decreased absorption of Atenolol due to formation of complexes caused by Sucralfate.	Acne vulgaris [ED80]	[68]
Dronedarone	DMA8FS5	Moderate	Increased risk of bradycardia by the combination of Atenolol and Dronedarone.	Angina pectoris [BA40]	[69]
Nifedipine	DMSVOZT	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nifedipine.	Angina pectoris [BA40]	[66]
Promazine	DMZAL7W	Moderate	Additive hypotensive effects by the combination of Atenolol and Promazine.	Appearance/behaviour symptom [MB23]	[70]
Ampicillin	DMHWE7P	Moderate	Altered absorption of Atenolol caused by Ampicillin.	Bacterial infection [1A00-1C4Z]	[71]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Atenolol and Cariprazine.	Bipolar disorder [6A60]	[70]
Atracurium	DM42HXN	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Atracurium.	Corneal disease [9A76-9A78]	[72]
Mivacurium	DM473VD	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Mivacurium.	Corneal disease [9A76-9A78]	[72]
Pancuronium	DMB0VY8	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Pancuronium.	Corneal disease [9A76-9A78]	[72]
Tubocurarine	DMBZIVP	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Tubocurarine.	Corneal disease [9A76-9A78]	[72]
Nimodipine	DMQ0RKZ	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nimodipine.	Coronary vasospastic disease [BA85]	[66]
Pasireotide	DMHM7JS	Moderate	Increased risk of atrioventricular block by the combination of Atenolol and Pasireotide.	Cushing syndrome [5A70]	[73]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Atenolol and OPC-34712.	Depression [6A70-6A7Z]	[70]
Hyoscyamine	DM804UR	Moderate	Antagonize the effect of Atenolol when combined with Hyoscyamine.	Digestive system disease [DE2Z]	[74]
Mepenzolate	DM8YU2F	Moderate	Antagonize the effect of Atenolol when combined with Mepenzolate.	Digestive system disease [DE2Z]	[74]
Oxybutynine	DMJPBAX	Moderate	Antagonize the effect of Atenolol when combined with Oxybutynine.	Discovery agent [N.A.]	[74]
Trihexyphenidyl	DMB19L8	Moderate	Antagonize the effect of Atenolol when combined with Trihexyphenidyl.	Dystonic disorder [8A02]	[74]
Ethacrynic acid	DM60QMR	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Ethacrynic acid.	Essential hypertension [BA00]	[67]
Bendroflumethiazide	DM7EVLC	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Bendroflumethiazide.	Essential hypertension [BA00]	[67]
Phenoxybenzamine	DM8KSQH	Moderate	Additive hypotensive effects by the combination of Atenolol and Phenoxybenzamine.	Essential hypertension [BA00]	[75]
Nicardipine	DMCDYW7	Moderate	Increased risk of cardiac depression by the combination of Atenolol and Nicardipine.	Essential hypertension [BA00]	[66]
Benzthiazide	DMQWZ0H	Moderate	Increased risk of hyperglycemia by the combination of Atenolol and Benzthiazide.	Essential hypertension [BA00]	[67]
Phenylephrine	DMZHUO5	Moderate	Additive hypertensive effects by the combination of Atenolol and Phenylephrine.	Faecal incontinence [ME07]	[76]
Tolterodine	DMSHPW8	Moderate	Antagonize the effect of Atenolol when combined with Tolterodine.	Functional bladder disorder [GC50]	[74]
Propantheline	DM2EN6G	Moderate	Antagonize the effect of Atenolol when combined with Propantheline.	Gastric ulcer [DA60]	[74]
Cimetidine	DMH61ZB	Moderate	Decreased metabolism of Atenolol caused by Cimetidine mediated inhibition of CYP450 enzyme.	Gastro-oesophageal reflux disease [DA22]	[77]
Spironolactone	DM2AQ5N	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Spironolactone.	Heart failure [BD10-BD1Z]	[67]
Triamterene	DM2HU9I	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Triamterene.	Heart failure [BD10-BD1Z]	[67]
Prazosin	DMCD9YG	Moderate	Additive hypotensive effects by the combination of Atenolol and Prazosin.	Heart failure [BD10-BD1Z]	[75]
Chlorothiazide	DMLHESP	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Chlorothiazide.	Heart failure [BD10-BD1Z]	[67]
Furosemide	DMMQ8ZG	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Furosemide.	Heart failure [BD10-BD1Z]	[67]
Bumetanide	DMRV7H0	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Bumetanide.	Heart failure [BD10-BD1Z]	[67]
Hydroflumethiazide	DMVPUQI	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Hydroflumethiazide.	Heart failure [BD10-BD1Z]	[67]
Belladonna	DM2RBWK	Moderate	Antagonize the effect of Atenolol when combined with Belladonna.	Infectious gastroenteritis/colitis [1A40]	[74]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Atenolol and ITI-007.	Insomnia [7A00-7A0Z]	[70]
Clidinium	DMUMQZ0	Moderate	Antagonize the effect of Atenolol when combined with Clidinium.	Irritable bowel syndrome [DD91]	[74]
Dicyclomine	DMZSDGX	Moderate	Antagonize the effect of Atenolol when combined with Dicyclomine.	Irritable bowel syndrome [DD91]	[74]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Atenolol due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[73]
Thalidomide	DM70BU5	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Thalidomide.	Multiple myeloma [2A83]	[78]
Siponimod	DM2R86O	Major	Increased risk of atrioventricular block by the combination of Atenolol and Siponimod.	Multiple sclerosis [8A40]	[78]
Fingolimod	DM5JVAN	Major	Increased risk of bradycardia by the combination of Atenolol and Fingolimod.	Multiple sclerosis [8A40]	[79]
Ozanimod	DMT6AM2	Moderate	Increased risk of atrioventricular block by the combination of Atenolol and Ozanimod.	Multiple sclerosis [8A40]	[80]
Prochlorperazine	DM53SRA	Moderate	Additive hypotensive effects by the combination of Atenolol and Prochlorperazine.	Nausea/vomiting [MD90]	[70]
Promethazine	DM6I5GR	Moderate	Additive hypotensive effects by the combination of Atenolol and Promethazine.	Nausea/vomiting [MD90]	[70]
Thiethylperazine	DMU3IET	Moderate	Additive hypotensive effects by the combination of Atenolol and Thiethylperazine.	Nausea/vomiting [MD90]	[70]
Metolazone	DMB39LO	Moderate	Increased risk of hypertriglyceridemia by the combination of Atenolol and Metolazone.	Oedema [MG29]	[67]
Polythiazide	DMCH80F	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Polythiazide.	Oedema [MG29]	[67]
Procyclidine	DMHFJDT	Moderate	Antagonize the effect of Atenolol when combined with Procyclidine.	Parkinsonism [8A00]	[74]
Methylscopolamine	DM5VWOB	Moderate	Antagonize the effect of Atenolol when combined with Methylscopolamine.	Peptic ulcer [DA61]	[74]
Terazosin	DM3JCVS	Moderate	Additive hypotensive effects by the combination of Atenolol and Terazosin.	Prostate hyperplasia [GA90]	[75]
Silodosin	DMJSBT6	Moderate	Additive hypotensive effects by the combination of Atenolol and Silodosin.	Prostate hyperplasia [GA90]	[75]
Alfuzosin	DMZVMKF	Moderate	Additive hypotensive effects by the combination of Atenolol and Alfuzosin.	Prostate hyperplasia [GA90]	[75]
Levomepromazine	DMIKFEL	Moderate	Additive hypotensive effects by the combination of Atenolol and Levomepromazine.	Psychotic disorder [6A20-6A25]	[70]
Fluphenazine	DMIT8LX	Moderate	Additive hypotensive effects by the combination of Atenolol and Fluphenazine.	Psychotic disorder [6A20-6A25]	[70]
Triflupromazine	DMKFQJP	Moderate	Additive hypotensive effects by the combination of Atenolol and Triflupromazine.	Psychotic disorder [6A20-6A25]	[70]
Mesoridazine	DM2ZGAN	Moderate	Additive hypotensive effects by the combination of Atenolol and Mesoridazine.	Schizophrenia [6A20]	[70]
Thioridazine	DM35M8J	Moderate	Additive hypotensive effects by the combination of Atenolol and Thioridazine.	Schizophrenia [6A20]	[70]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Atenolol and Aripiprazole.	Schizophrenia [6A20]	[70]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Atenolol and Iloperidone.	Schizophrenia [6A20]	[70]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Atenolol and Paliperidone.	Schizophrenia [6A20]	[70]
Loxapine	DM8AI9U	Moderate	Additive hypotensive effects by the combination of Atenolol and Loxapine.	Schizophrenia [6A20]	[70]
Haloperidol	DM96SE0	Moderate	Additive hypotensive effects by the combination of Atenolol and Haloperidol.	Schizophrenia [6A20]	[70]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Atenolol and Molindone.	Schizophrenia [6A20]	[70]
Chlorpromazine	DMBGZI3	Moderate	Additive hypotensive effects by the combination of Atenolol and Chlorpromazine.	Schizophrenia [6A20]	[70]
Thiothixene	DMDINC4	Moderate	Additive hypotensive effects by the combination of Atenolol and Thiothixene.	Schizophrenia [6A20]	[70]
Trifluoperazine	DMKBYWI	Moderate	Additive hypotensive effects by the combination of Atenolol and Trifluoperazine.	Schizophrenia [6A20]	[70]
Risperidone	DMN6DXL	Moderate	Additive hypotensive effects by the combination of Atenolol and Risperidone.	Schizophrenia [6A20]	[70]
Amisulpride	DMSJVAM	Moderate	Increased risk of ventricular arrhythmias by the combination of Atenolol and Amisulpride.	Schizophrenia [6A20]	[74]
Pipecuronium	DM5F84A	Moderate	Additive cardiorespiratory depression effects by the combination of Atenolol and Pipecuronium.	Tonus and reflex abnormality [MB47]	[72]
Doxacurium	DMKE7L9	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Doxacurium.	Tonus and reflex abnormality [MB47]	[72]
Vecuronium	DMP0UK2	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Vecuronium.	Tonus and reflex abnormality [MB47]	[72]
Cisatracurium	DMUZPJ5	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Cisatracurium.	Tonus and reflex abnormality [MB47]	[72]
Rocuronium	DMY9BMK	Moderate	Additive neuromuscular blocking effects by the combination of Atenolol and Rocuronium.	Tonus and reflex abnormality [MB47]	[72]
Atropine	DMEN6X7	Moderate	Antagonize the effect of Atenolol when combined with Atropine.	Unspecific substance harmful effect [NE6Z]	[74]
Methdilazine	DMAUHQX	Moderate	Additive hypotensive effects by the combination of Atenolol and Methdilazine.	Vasomotor/allergic rhinitis [CA08]	[70]
Trimeprazine	DMEMV9D	Moderate	Additive hypotensive effects by the combination of Atenolol and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[81]
Amiodarone	DMUTEX3	Moderate	Increased risk of bradycardia by the combination of Atenolol and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[82]
-----------


⏷ Show the Full List of 77 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Kyselina citronova	E00014	311	Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Glycerin	E00026	753	Antimicrobial preservative; Emollient; Flavoring agent; Humectant; Lubricant; Plasticizing agent; Solvent; Suppository base; Tonicity agent; Viscosity-controlling agent
Magnesium carbonate	E00205	11029	Adsorbent; Diluent
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Vinylpyrrolidone	E00668	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Atenolol 100 mg tablet	100 mg	Oral Tablet	Oral
Atenolol 25 mg tablet	25 mg	Oral Tablet	Oral
Atenolol 50 mg tablet	50 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 548).
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 072303.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Kirch W, Gorg KG: Clinical pharmacokinetics of atenolol--a review. Eur J Drug Metab Pharmacokinet. 1982;7(2):81-91. doi: 10.1007/BF03188723.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Kharasch ED, Thummel KE: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane, and methoxyflurane. Anesthesiology. 1993 Oct;79(4):795-807.
8	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
9	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
10	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
11	Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
12	Fruit juice inhibition of uptake transport: a new type of food-drug interaction. Br J Clin Pharmacol. 2010 Nov;70(5):645-55.
13	Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500.
14	Metabolism of atenolol in man. Xenobiotica. 1978 May;8(5):313-20.
15	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
16	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
18	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
19	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
20	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
21	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
22	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
24	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
26	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
27	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
28	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
29	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
30	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
31	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
32	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
33	Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
34	MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
35	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
36	Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
37	Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
38	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
39	Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
40	Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
41	Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
42	Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
43	Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
44	Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
45	Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
46	Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
47	Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
48	Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
49	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
50	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
51	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
52	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
53	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
54	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
55	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
56	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
57	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
58	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
59	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
60	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
61	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
62	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
63	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
64	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
65	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
66	Anastassiades CJ "Nifedipine and beta-blocker drugs." Br Med J 281 (1980): 1251-2. [PMID: 6107167]
67	Dean S, Kendall MJ, Potter S, Thompson MH, Jackson DA "Nadolol in combination with indapamide and xipamide in resistant hypertensives." Eur J Clin Pharmacol 28 (1985): 29-33. [PMID: 3987783]
68	D'Arcy PF, McElnay JC "Drug-antacid interactions: assessment of clinical importance." Drug Intell Clin Pharm 21 (1987): 607-17. [PMID: 2886325]
69	Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
70	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]
71	McLean AJ, Tonkin A, McCarthy P, Harrison P "Dose-dependence of atenolol-ampicillin interaction." Br J Clin Pharmacol 18 (1984): 969-71. [PMID: 6529538]
72	Chapple DJ, Clark JS, Hughes R "Interaction between atracurium and drugs used in anaesthesia." Br J Anaesth 55 Suppl 1 (1983): s17-22. [PMID: 6688011]
73	Canadian Pharmacists Association.
74	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
75	Chrysant SG "Experience with terazosin administered in combination with other antihypertensive agents." Am J Med 80 (1986): 55-61. [PMID: 2872808]
76	Cass E, Kadar D, Stein HA "Hazards of phenylephrine topical medication in persons taking propranolol." Can Med Assoc J 120 (1979): 1261-2. [PMID: 221086]
77	Asgharnejad M, Powell R, Donn K, Danis M "The effect of cimetidine dose timing on oral propranolol kinetics in adults." Clin Pharmacol Ther 41 (1987): 203. [PMID: 3392231]
78	Cerner Multum, Inc. "Australian Product Information.".
79	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
80	Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
81	Product Information. Clozaril (clozapine). Novartis Pharmaceuticals, East Hanover, NJ.
82	Leor J, Levartowsky D, Sharon C, Farfel Z "Amiodarone and beta-adrenergic blockers: an interaction with metoprolol but not with atenolol." Am Heart J 16 (1988): 206-7. [PMID: 3394625]